Education
About Us
Working with TipRanks
Follow Us
MAIA Biotechnology, Inc. (MAIA)
:MAIA
Cemiplimab, Docetaxel, Vinorelbine, 6-Thio-2'-Deoxyguanosine, Gemcitabine Alone
Carcinoma, Non-Small -Cell Lung
Phase III
Not Yet Recruiting
A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC
Mar 20, 2025
―
Cemiplimab, 6-Thio-2'-Deoxyguanosine
Carcinoma, Non-small-cell Lung
Phase II
Recruiting
THIO Sequenced With Cemiplimab in Advanced NSCLC
Dec 05, 2021
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does MAIA Biotechnology, Inc. (MAIA) have in its pipeline
MAIA is currently developing the following drugs: Cemiplimab, Docetaxel, Vinorelbine, 6-Thio-2'-Deoxyguanosine, Gemcitabine Alone, Cemiplimab, 6-Thio-2'-Deoxyguanosine. These drug candidates are in various stages of clinical development as the company works toward FDA approval.